Vaccines,
Год журнала:
2022,
Номер
10(9), С. 1504 - 1504
Опубликована: Сен. 9, 2022
Several
vaccines
against
COVID-19
are
now
available,
based
on
different
techniques
and
made
by
laboratories
spread
around
the
world.
With
roll
out
of
vaccination
process
in
an
advanced
stage
many
countries,
reduced
risk
hospitalization
due
to
Omicron
variant
relative
Delta
infection,
despite
higher
transmission
Omicron,
may
lead
a
misinterpretation
results,
as
infection
is
associated
with
significant
reduction
severe
outcomes
shorter
time
than
variant.
We
compared
in-hospital
mortality
(Jan-Mar
2022)
Gamma
(Jan
2021)
(Oct-Dec
variants
patients
Brazilian
public
health
system.
This
study
also
discusses
decrease
booster
vaccine
effectiveness
hospitalized
Without
remodeling
for
new
variants,
doses
be
necessary
interval.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Март 7, 2024
Abstract
The
membrane
(M)
protein
of
betacoronaviruses
is
well-conserved
and
plays
a
key
role
in
viral
assembly.
Here,
we
describe
the
discovery
JNJ-9676,
novel
small
molecule
targeting
coronaviral
(CoV)
M
protein.
JNJ-9676
demonstrates
in
vitro
nanomolar
antiviral
activity
against
SARS-CoV2,
SARS-CoV,
sarbecovirus
strains
from
bat
pangolin
zoonotic
origin.
Using
cryogenic
electron
microscopy,
determined
binding
pocket
protein's
transmembrane
domain.
Compound
stabilized
an
altered
conformational
state
between
its
long-
short-forms,
preventing
release
infectious
virus.
In
pre-exposure
Syrian
golden
hamster
model,
(25
mg/kg
BID)
showed
excellent
efficacy
illustrated
by
significant
reduction
load
virus
lung
3.5
log10
4
log10,
respectively.
Histopathology
scores
at
this
dose
were
reduced
to
baseline.
post-exposure
was
efficacious
75mg/kg
BID
even
when
added
48
h
post-infection,
peak
loads
observed.
attractive
target
block
coronavirus
replication
with
representing
interesting
chemical
series
towards
identifying
clinical
candidates
addressing
current
future
CoV
pandemics.
Clinical and Experimental Vaccine Research,
Год журнала:
2024,
Номер
13(1), С. 68 - 68
Опубликована: Янв. 1, 2024
In
the
context
of
massive
spread
coronavirus
disease
2019
(COVID-19),
development
a
COVID-19
vaccine
is
urgently
needed.
The
Pfizer-BioNTech
has
been
widely
applied
across
global
populations.
Herein,
we
report
case
acute
interstitial
nephritis
with
kidney
injury
in
young
healthy
subject
after
administration
vaccine.
A
20-year-old
man
was
admitted
abdominal
discomfort
and
nausea.
He
had
received
6
days
before.
At
9
vaccination,
his
function
decreased,
serum
creatinine
levels
1.8
mg/dL.
Even
supportive
care
hydration,
worsened,
he
underwent
biopsy.
pathology
findings
revealed
diffuse
infiltration
inflammatory
cells,
predominantly
comprising
lymphocytes,
preservation
glomerulus.
No
abnormal
were
noted
by
immunofluorescence
or
electron
microscopy.
Based
on
diagnosis
drug-related
nephritis,
treated
patient
high-dose
prednisolone.
After
prednisolone,
slowly
improved.
close
linkage
between
vaccination
should
be
considered
clinic,
despite
low
incidence.
Expert Opinion on Therapeutic Patents,
Год журнала:
2024,
Номер
34(3), С. 171 - 186
Опубликована: Март 3, 2024
Introduction
Nucleic
acid-based
therapeutics
offer
groundbreaking
potential
for
treating
genetic
diseases
and
advancing
next-generation
vaccines.
Despite
their
promise,
challenges
in
efficient
delivery
persist
due
to
the
properties
of
nucleic
acids.
Nanoparticles
(NPs)
serve
as
vital
carriers,
facilitating
effective
target
cells,
addressing
these
challenges.
Understanding
global
landscape
patents
this
field
is
essential
fostering
innovation
guiding
decision-making
researchers,
pharmaceutical
industry,
regulatory
agencies.
Vaccines,
Год журнала:
2022,
Номер
10(9), С. 1504 - 1504
Опубликована: Сен. 9, 2022
Several
vaccines
against
COVID-19
are
now
available,
based
on
different
techniques
and
made
by
laboratories
spread
around
the
world.
With
roll
out
of
vaccination
process
in
an
advanced
stage
many
countries,
reduced
risk
hospitalization
due
to
Omicron
variant
relative
Delta
infection,
despite
higher
transmission
Omicron,
may
lead
a
misinterpretation
results,
as
infection
is
associated
with
significant
reduction
severe
outcomes
shorter
time
than
variant.
We
compared
in-hospital
mortality
(Jan-Mar
2022)
Gamma
(Jan
2021)
(Oct-Dec
variants
patients
Brazilian
public
health
system.
This
study
also
discusses
decrease
booster
vaccine
effectiveness
hospitalized
Without
remodeling
for
new
variants,
doses
be
necessary
interval.
